CL2008000380A1 - PHARMACEUTICAL COMPOSITION INCLUDING A MUSCARINIC ANTAGONIST AND A BETA 2-ADRENOCEPTOR ANTAGONIST; PHARMACEUTICAL KIT THAT INCLUDES SUCH PHARMACEUTICAL COMPOSITION; AND ITS USE TO TREAT A CHRONIC OBSTRUCTIVE PULMONARY DISEASE. - Google Patents

PHARMACEUTICAL COMPOSITION INCLUDING A MUSCARINIC ANTAGONIST AND A BETA 2-ADRENOCEPTOR ANTAGONIST; PHARMACEUTICAL KIT THAT INCLUDES SUCH PHARMACEUTICAL COMPOSITION; AND ITS USE TO TREAT A CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Info

Publication number
CL2008000380A1
CL2008000380A1 CL200800380A CL2008000380A CL2008000380A1 CL 2008000380 A1 CL2008000380 A1 CL 2008000380A1 CL 200800380 A CL200800380 A CL 200800380A CL 2008000380 A CL2008000380 A CL 2008000380A CL 2008000380 A1 CL2008000380 A1 CL 2008000380A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
antagonist
pharmaceutical
beta
treat
Prior art date
Application number
CL200800380A
Other languages
Spanish (es)
Inventor
John Finch Harry Wiley K Dixon
Original Assignee
Astrazeneca Ab Argenta Discove
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37898913&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000380(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab Argenta Discove filed Critical Astrazeneca Ab Argenta Discove
Publication of CL2008000380A1 publication Critical patent/CL2008000380A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL200800380A 2007-02-07 2008-02-06 PHARMACEUTICAL COMPOSITION INCLUDING A MUSCARINIC ANTAGONIST AND A BETA 2-ADRENOCEPTOR ANTAGONIST; PHARMACEUTICAL KIT THAT INCLUDES SUCH PHARMACEUTICAL COMPOSITION; AND ITS USE TO TREAT A CHRONIC OBSTRUCTIVE PULMONARY DISEASE. CL2008000380A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0702385.6A GB0702385D0 (en) 2007-02-07 2007-02-07 New combination

Publications (1)

Publication Number Publication Date
CL2008000380A1 true CL2008000380A1 (en) 2008-08-18

Family

ID=37898913

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200800380A CL2008000380A1 (en) 2007-02-07 2008-02-06 PHARMACEUTICAL COMPOSITION INCLUDING A MUSCARINIC ANTAGONIST AND A BETA 2-ADRENOCEPTOR ANTAGONIST; PHARMACEUTICAL KIT THAT INCLUDES SUCH PHARMACEUTICAL COMPOSITION; AND ITS USE TO TREAT A CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Country Status (18)

Country Link
US (1) US20110046191A1 (en)
EP (1) EP2124941A1 (en)
JP (1) JP5337054B2 (en)
KR (1) KR20090114389A (en)
CN (2) CN101636390B (en)
AR (1) AR065202A1 (en)
AU (1) AU2008212649B2 (en)
BR (1) BRPI0806966A2 (en)
CA (1) CA2675718A1 (en)
CL (1) CL2008000380A1 (en)
GB (1) GB0702385D0 (en)
MX (1) MX2009008363A (en)
PE (1) PE20081751A1 (en)
RU (1) RU2460527C2 (en)
TW (1) TW200901986A (en)
UA (1) UA99604C2 (en)
WO (1) WO2008096126A1 (en)
ZA (1) ZA200905106B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0516313D0 (en) * 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
GB0704000D0 (en) * 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
BRPI0822693A2 (en) 2008-05-13 2015-07-07 Astrazeneca Ab Quinuclidine derivatives as m3 muscarinic receptor antagonists
CN102131505A (en) * 2008-06-20 2011-07-20 阿斯利康(瑞典)有限公司 Pharmaceutical composition comprising a 4-hydroxy-2-oxo-2, 3- dihydro-1, 3-benzothiazol-7-yl compound for modulation of beta2-adrenoreceptor activity
GB0814728D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
GB0823140D0 (en) * 2008-12-18 2009-01-28 Astrazeneca Ab New combination
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
WO2011011060A1 (en) 2009-07-22 2011-01-27 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
CA3180743A1 (en) 2018-09-28 2020-04-02 Karuna Therapeutics, Inc. Composition comprising xanomeline and trospium for treating disorders ameliorated by muscarinic receptor activation
CN109896934A (en) * 2019-03-08 2019-06-18 山东省药学科学院 A kind of preparation method of high-purity 2- benzyloxy bromoethane

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307141B1 (en) * 1987-09-10 1993-01-13 MERCK SHARP & DOHME LTD. Oxazoles and thiazoles for the treatment of senile dementia
FR2675142B1 (en) * 1991-04-10 1993-06-25 Roussel Uclaf NOVEL DERIVATIVES OF ALPHA-METHYLENE 4 - [(PHENOXY) METHYL] 5-THIAZOLACETIC ACID, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF AND THEIR APPLICATION AS FUNGICIDES.
GB9603755D0 (en) * 1996-02-22 1996-04-24 Pfizer Ltd Therapeutic agents
US6057340A (en) * 1998-02-03 2000-05-02 American Home Products Corporation Oxazole derivatives as serotonin-1A receptor agonists
US6242448B1 (en) * 1998-12-17 2001-06-05 American Home Products Corporation Trisubstituted-oxazole derivatives as serotonin ligands
SE9902935D0 (en) * 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
US20020189610A1 (en) * 2001-02-01 2002-12-19 Karl-Heinz Bozung Pharmaceutical compositions containing an ipratropium salt and a betamimetic
US20020179087A1 (en) * 2001-02-01 2002-12-05 Karl-Heinz Bozung Pharmaceutical compositions containing an oxitropium salt and a betamimetic
US7417051B2 (en) * 2002-04-12 2008-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising betamimetics and a novel anticholinergic
EP2319584A1 (en) * 2002-08-29 2011-05-11 Cipla Ltd. Pharmaceutical products and compositions comprising salmeterol, ciclesonide and tiotropium
US7332175B2 (en) * 2003-05-27 2008-02-19 Boehringer Ingelheim International Gmbh Long-acting drug combinations for the treatment of respiratory complaints
US20050025718A1 (en) * 2003-07-31 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US7745621B2 (en) * 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
GB0516313D0 (en) * 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
TW200738658A (en) * 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
WO2008017827A2 (en) * 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
WO2008096093A1 (en) * 2007-02-06 2008-08-14 Argenta Discovery Ltd. Oxazole and thiazole derivatives and their uses

Also Published As

Publication number Publication date
CN101636390A (en) 2010-01-27
WO2008096126A1 (en) 2008-08-14
PE20081751A1 (en) 2008-12-27
BRPI0806966A2 (en) 2014-04-08
ZA200905106B (en) 2010-05-26
TW200901986A (en) 2009-01-16
CN101678005B (en) 2012-10-31
JP5337054B2 (en) 2013-11-06
KR20090114389A (en) 2009-11-03
GB0702385D0 (en) 2007-03-21
JP2010518059A (en) 2010-05-27
CN101678005A (en) 2010-03-24
AU2008212649B2 (en) 2011-05-19
AR065202A1 (en) 2009-05-20
RU2460527C2 (en) 2012-09-10
RU2009133261A (en) 2011-03-20
MX2009008363A (en) 2009-08-20
CN101636390B (en) 2013-06-12
US20110046191A1 (en) 2011-02-24
UA99604C2 (en) 2012-09-10
AU2008212649A1 (en) 2008-08-14
CA2675718A1 (en) 2008-07-14
EP2124941A1 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
CL2008000380A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A MUSCARINIC ANTAGONIST AND A BETA 2-ADRENOCEPTOR ANTAGONIST; PHARMACEUTICAL KIT THAT INCLUDES SUCH PHARMACEUTICAL COMPOSITION; AND ITS USE TO TREAT A CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
BRPI0818193A2 (en) compound, pharmaceutically acceptable salt of a compound, pharmaceutical composition, and use of a compound
CL2007002967A1 (en) CRYSTAL FORM A OF THE COMPOUND 4- [3- (4-CYCLOPROPANCARBONIL-PIPERAZIN-1-CARBONIL) -4-FLUORO-BENCIL] -2H-FTALAZIN-1-ONA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF A
DK1984009T3 (en) Pharmaceutical compositions with improved stability
BRPI0720124A2 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE.
CL2008000510A1 (en) FARMACO-LIGANDOS CONJUGATED COMPOUNDS, THAT JOIN POWERFUL CITOTOXINS; PHARMACEUTICAL COMPOSITION; AND USE TO DELAY OR STOP THE GROWTH OF A TUMOR IN A MAMMER.
CL2007001992A1 (en) COMPOUNDS DERIVED FROM PYRIMIDILCICLOPENTANOS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF AN INFLAMMATORY, HYPERPROLIFERANT, CARDIOVASCULAR, NEURODEGE DISEASE
BRPI0917540A2 (en) compound, pharmaceutically acceptable salt, pharmaceutical composition, and use of a pharmacologically acceptable compound or salt
CL2007002752A1 (en) COMPOUNDS DERIVED FROM 3- (4-OXO-4H-QUINAZOLIN-3-IL) -PIPERIDINA-2,6-DIONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT OR PREVENT DISEASES SUCH AS CANCER, PAIN, MACULAR DEGENERATION, PULMONARY DISORDER, TR
BRPI0813456A2 (en) COMPOSITION, USE OF THE SAME, PHARMACEUTICAL COMPOSITION, AND METHODS TO TREAT A MAMMAL WITH A DISORDER AND DISEASE
BRPI0810696A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND
CL2013000801A1 (en) Pharmaceutical composition comprising a rankl inhibitor and a hormone or a derivative thereof, and use of the rankl inhibitor to prepare said composition
BRPI0817200A2 (en) solid ophthalmic compositions and use of pharmaceutical manufacturing compounds
BRPI0813955A2 (en) therapeutic compositions and their use
BRPI0811865A2 (en) HYPEROCYCLIC HYPEROCYCLIC DERIVATIVES, THE PREPARATION AND PHARMACEUTICAL USE OF THE SAME
BRPI0810161A2 (en) COMPOUND, PHARMACEUTICAL PREPARATION, PHARMACEUTICAL COMPOSITION, AND USE OF A COMPOUND
CL2008000408A1 (en) INHIBITING PIRROLIDIN-AMIDA DERIVATIVE COMPOUNDS OF THE PROTEASA ACTIVADORA DE CANAL; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT CHYSICAL FIBROSIS, CHRONIC BRONCHITIS, LUNG CANCER BETWEEN OTHER DISEASES
CL2007003260A1 (en) COMPOUNDS DERIVED FROM AZABICICLO [2.2.2] OCTANO; PROCEDURE FOR PREPARATION OF SUCH COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
BRPI0816389A2 (en) COMPOSITIONS OF FILTABLE FUNGAL TOTAL CELLULASE EMPLOYED BY BETA GLYCOSITY AND METHODS OF USE
BRPI0814769A2 (en) SYNERGIC COMPOSITION UNDERSTANDING FLAVORING SUBSTANCES AND ORGANIC ACIDS AND USE OF THE SAME
ATE493119T1 (en) PHARMACEUTICAL COMPOSITION
BRPI0815821A2 (en) COMPOSITIONS AND METHODS USING NMDA ANTAGONISTS TO ACHIEVE ANESTHETICS SAVING EFFECT.
IT1403847B1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING RIFAXIMINA AND THEIR USE.
CL2008000060A1 (en) COMPOUNDS DERIVED FROM 1-CARBOXI-2-AMIDA PIRROLIDINE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT CHYSICAL FIBROSIS, PULMONARY CARCINOMA, CHRONIC BRONCHITIS, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA OR AN INF
CL2007002494A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES A PIRIMIDINE TRISUSTITUIDA IN COMBINATION WITH A COMPOUND WITH INHIBITORY PROPERTIES OF PDE5; AND USE IN THE TREATMENT OF A DISEASE THAT INVOLVES VASOCONSTRICTION.